Page last updated: 2024-11-12
germacradienol
Description
germacradienol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(1E,4S,5E,7R)-germacra-1(10),5-dien-11-ol : A germacrane sesquiterpenoid obtained from germacrane by hydroxylation at C(11) together with dehydrogenation across the C(1)-C(10) and C(5)-C(6) bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (8)
| Synonym |
|---|
| germacradienol |
| (1e,4s,5e,7r)-germacra-1(10),5-dien-11-ol |
| 2-[(1r,2e,4s,7e)-4,8-dimethylcyclodeca-2,7-dien-1-yl]propan-2-ol |
| CHEBI:46734 |
| (4s,7r)-germacra-1(10)e,5e-diene-11-ol |
| LMPR0103090009 |
| ZVZPKUXZGROCDB-BRNABIDRSA-N |
| Q27120690 |
Research Excerpts
Overview
Germacradienol is a main precursor in the biosynthesis of geosmin-type terpenes by a variety of microbes. Its biological activities are still unknown.
| Excerpt | Reference | Relevance |
|---|
| "Germacradienol is a main precursor in the biosynthesis of geosmin-type terpenes by a variety of microbes, but its biological activities are still unknown. " | ( The discovery of germacradienol synthase: Construction of genetically-engineered strain, glycosylated modification, bioactive evaluation of germacradienol.
Chen, X; Han, L; Huang, X; Jiang, C; Jiang, Y; Li, G; Wu, M; Yin, M; Zhang, Z, 2022) | 2.5 |
Drug Classes (2)
| Class | Description |
|---|
| germacrane sesquiterpenoid | Any sesquiterpenoid having a germacrane skeleton. |
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.10
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 20.10 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.55 (4.65) | | Search Engine Demand Index | 15.26 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |